Characteristics of the post-infarction period in obese patients after percutaneous coronary intervention

Abstract

Annotation. The study on the metabolic profile in the long-term period after myocardial infarction with comorbidity is relevant. The aim of the work was to examine metabolic profile and echocardiographic parameters in patients with ST-elevation myocardial infarction (STEMI) and obesity following percutaneous coronary intervention (PCI) after a 1-year follow-up. A total of 60 patients with STEMI and obesity were examined. The first subgroup consisted of 20 patients with medicamentous therapy, and the second group – 38 patients with PCI. Adropin, irisin, fatty acid-binding protein 4 (FABP4), C1q/tumor necrosis factor-related protein-3 (CTRP3) were measured by the enzyme-linked immunosorbent assay. The statistical processing of the study results obtained was carried out using the software package “IBM SPPS Statistics 27.0”. The following parameters were increased in patients who received combined medicamentous and PCI therapy before and after the treatment (p<0.05): end-diastolic size (EDS) (by 16.83% and 10.89%, respectively), end-diastolic volume (EDV) (by 45.95% and 18.92% respectively), end-systolic volume (ESV) (by 40.0% and 27.69%, respectively), stroke volume (SV) (by 33.85% and 18.46%, respectively), left ventricular myocardial mass index (LVMMI) (by 18.93% and 10.06%, respectively), adropin (by 27.13% and 47.21%, respectively), irisin (by 2.07 times and 2.75 times, respectively) and CTRP3 (by 15.98 % and 31.96%, respectively), while the following parameters were decreased: systolic blood pressure (by 16.0% and 16.67%, respectively), diastolic blood pressure (by 15.56% and 14.44%, respectively), insulin (by 40 .38% and 48.59%, respectively), glucose (by 10.97% and 15.74%, respectively), atherogenic index (by 6.03% and 12.33%, respectively). Thus, patients with post-infarction cardiosclerosis and obesity have been revealed with increased echocardiographic parameters and imbalanced energy and adipokine metabolism.